Skip to content
ClosedNo longer accepting applications

Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2

DEPT OF DEFENSE

About this archived opportunity

UPDATE: Clarification regarding program coordination across Task Areas (Sections 1.3 and 2.5), clarification of the acquisition strategy (Section 2.1), and removal of broken links to tables, figures, and footnotes. The Resuscitation and Prevention of Ischemia-induced Dysfunction (RAPIID) program seeks to deliver a transformative, end-to-end resuscitation system that redefines far-forward trauma care. RAPIID aims for this system to be fieldable, usable, and scalable, providing a capability equivalent or superior to stored whole blood in early resuscitation while removing dependence on cold chain and donor logistics. RAPIID seeks to do this by developing a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines (CPGs). To maximize post-program viability of developed products, RAPIID will develop and execute effective regulatory and commercialization strategies and accelerate advanced development through technology readiness level (TRL) 7 (Scale-up and Phase II Clinical Trials)1 for blood analog components and TRL 8 (Clinical Studies)2 for devices and diagnostics. This solicitation is to request proposals addressing ONLY Phase 1 of Task Area (TA)-1 and/or TA-2.

Historical details

Status
Closed
Deadline
June 24, 2026
First captured
May 29, 2026
Publisher reference
13dca662b7da444593550da9d021d533

This opportunity has closed

Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2

by DEPT OF DEFENSE

Get notified when similar opportunities open

We'll save this search and email you when new resuscitation, prevention, ischemia opportunities are posted. Free.

Refine this search